奈替米星治疗革兰阴性菌感染的临床疗效与毒性
Clinical efficacy and toxicity of netilmicin in the treatment of gram-negative infections.
作者信息
Buckwold F J, Ronald A R, Lank B, Thompson L, Fox L, Harding G K
出版信息
Can Med Assoc J. 1979 Jan 20;120(2):161-7.
Netilmicin, a new semisynthetic aminoglycoside antibiotic, was used to treat 41 infections in 38 patients. The outcome of four infections could not be evaluated: two patients received inadequate therapy and two did not have gram-negative infections. Clinical improvement occurred in 36 (97%) of the 37 gram-negative infections, and bacteriologic cure occurred in 30 (86%) of the 35 evaluable infections. Therapeutic serum concentrations of netilmicin were readily achieved by both intramuscular and intravenous routes. Reversible ototoxic effects occurred in 1 (3%) of 35 courses of therapy evaluated, reversible nephrotoxic effects occurred in 5 (14%) of 36 courses and mild reversible alterations in liver function occurred in 3 (19%) of 34 courses. Netilmicin appears to be effective and safe in the treatment of aerobic gram-negative infections.
奈替米星是一种新型半合成氨基糖苷类抗生素，用于治疗38例患者的41次感染。4次感染的结果无法评估：2例患者治疗不充分，2例没有革兰氏阴性菌感染。37例革兰氏阴性菌感染中的36例（97%）临床症状改善，35例可评估感染中的30例（86%）细菌学治愈。肌内和静脉途径均能轻松达到奈替米星的治疗血清浓度。在评估的35个疗程中，1例（3%）出现可逆性耳毒性作用，36个疗程中有5例（14%）出现可逆性肾毒性作用，34个疗程中有3例（19%）出现轻度可逆性肝功能改变。奈替米星在治疗需氧革兰氏阴性菌感染方面似乎有效且安全。
Zotero 插件